PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

May 18, 2023 by Leave a Comment

Last Updated on May 18, 2023 by

[#item_full_content]

Spread the word

You must log in to post a comment.

We provide a balanced view on small cap biotech equities

Address : Santa Fe, New Mexico.

Generated by Feedzy

%d bloggers like this:

Reader Interactions